Method of treating cancer associated with a ras mutation
AssigneeBeyondSpring Pharmaceuticals, Inc.
InventorLan Huang
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.
Claims20
A method of treating a cancer characterized by expressing a mutant form of a RAS protein, comprising administering Plinabulin to a subject in need thereof, wherein:
- the mutant form of the RAS protein is a mutant form of a NRAS protein, a mutant form of an HRAS protein, or a mutant form of a KRAS protein that comprises one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12D, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61R, Q61H, K117N, A146P, A146T, A146V, and D153V.
A method of inhibiting proliferation of a cell having a RAS mutation, comprising contacting the cell with Plinabulin, wherein:
- the mutant form of the RAS protein is a mutant form of a NRAS protein, a mutant form of an HRAS protein, or a mutant form of a KRAS protein that comprises one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12D, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61R, Q61H, K117N, A146P, A146T, A146V, and D153V.
A method of inducing apoptosis in a cell having a RAS mutation, comprising contacting the cell with Plinabulin, wherein:
- the mutant form of the RAS protein is a mutant form of a NRAS protein, a mutant form of an HRAS protein, or a mutant form of a KRAS protein that comprises one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12D, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61R, Q61H, K117N, A146P, A146T, A146V, and D153V.
A method of inhibiting progression of a cancer characterized by expressing a mutant form of a RAS protein in a subject, comprising administering Plinabulin to a subject in need thereof, wherein
- the mutant form of the RAS protein is a mutant form of a NRAS protein, a mutant form of an HRAS protein, or a mutant form of a KRAS protein that comprises one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12D, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61R, Q61H, K117N, A146P, A146T, A146V, and D153V.
Dependencies are inferred from the claim text.